Delivery Order SPE2DB20D1100-SPE2DB25FA9A3

Award Date 3/4/25
Potential Completion Date 3/5/25
Potential Value $3.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,508.82 firm fixed-price delivery order is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a pharmaceutical product. The contract has an ultimate completion date of July 17, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,684.95 firm fixed-price delivery order is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a specialty medication. The contract has an ultimate completion date of March 4, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,186.24 firm fixed-price delivery order contract is for the product QUILLIVANT XR 25 MG/5 ML SUSP 150ML. The award does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,742.48 firm fixed-price delivery order is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 150ML, a specialty pharmaceutical product. The order has an ultimate completion date of November 13, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,730.20 firm-fixed-price delivery order is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a medication, with a completion date of September 13, 2024. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,524.36 firm fixed price delivery order covers the supply of Quillivant XR 25 mg/5 ml suspension, a specialty medication. This award is associated with Amerisourcebergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,853.49 firm fixed-price delivery order is for the supply of QUILLIVANT XR 25 MG/5 ML SUSP 120ML, a pharmaceutical product, with an ultimate completion date of October 18, 2024. The award is not associated with a set-aside program. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,378.06 Firm Fixed Price Delivery Order is for the pharmaceutical product QUILLIVANT XR 25 MG/5 ML SUSP 60ML, with a completion date of January 30, 2025. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,816.72 firm-fixed-price delivery order is for the supply of QUILLIVANT XR ORAL SUSP 60ML 5MG/ML, a pharmaceutical product. The contract has an ultimate completion date of August 29, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,022.52 Firm Fixed Price Delivery Order is for the provision of QUILLIVANT XR 25 MG/5 ML SUSP 180ML, a specialty pharmaceutical product. The contract has an ultimate completion date of December 10, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB25FA9A3
    Delivery Order

This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,403.31 firm fixed-price delivery order is for the pharmaceutical product QUILLIVANT XR 25 MG/5 ML SUSP 150ML. The award is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 6/3/25, 9:48 AM